P/E ratio for Edwards Lifesciences (EW)
P/E ratio as of December 2023 (TTM): 29.6
According to Edwards Lifesciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 29.5702. At the end of 2022 the company had a P/E ratio of 30.5.
P/E ratio history for Edwards Lifesciences from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 30.5 | -43.11% |
| 2021 | 53.5 | -22.54% |
| 2020 | 69.1 | 49.02% |
| 2019 | 46.4 | 4.16% |
| 2018 | 44.5 | 16.54% |
| 2017 | 38.2 | 8.87% |
| 2016 | 35.1 | 1.98% |
| 2015 | 34.4 | 106.95% |
| 2014 | 16.6 | -11.75% |
| 2013 | 18.8 | -46.71% |
| 2012 | 35.4 | 3.53% |
| 2011 | 34.2 | -18.88% |
| 2010 | 42.1 | 97.31% |
| 2009 | 21.3 | -10.29% |
| 2008 | 23.8 | 1.9% |
| 2007 | 23.3 | 10.18% |
| 2006 | 21.2 | -32.27% |
| 2005 | 31.3 | -96.97% |
| 2004 | > 1000 | 4495.59% |
| 2003 | 22.4 | -18.04% |
| 2002 | 27.4 | -117.84% |
| 2001 | -153 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Medtronic MDT | 29.1 | -1.73% | 🇮🇪 Ireland |
 Boston Scientific BSX | 66.9 | 126.08% | 🇺🇸 USA |
 Merit Medical MMSI | 39.4 | 33.31% | 🇺🇸 USA |
 LeMaitre Vascular LMAT | 44.1 | 49.13% | 🇺🇸 USA |
 ICU Medical
ICUI | -42.7 | -244.46% | 🇺🇸 USA |
 CryoLife CRY | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.